HOUSTON, March 26, 2015 /PRNewswire/ -- The Burzynski
Research Institute, Inc. (BRI) announced today that results of
a study independently conducted by the Department of Surgery at
Kurume University Medical Center in Japan have been published. The study, a
randomized non-blinded phase 2 trial, compared 5-fluorouracil
hepatic arterial infusion as post-operative adjuvant therapy with
and without Antineoplastons A10/AS2-1 Injections for colorectal
metastasis of the liver.
A total of 65 patients, with histologically confirmed metastatic
colon adenocarcinoma of the liver, were evaluated. Primary
endpoints included cancer-specific survival. Secondary endpoints
included relapse-free survival, clinical status and extent of
recurrence, salvage surgery rate and toxicity.
BRI believes that the completion of the study represents an
important milestone in the development of Antineoplastons and that
further efficacy trials of Antineoplastons in colorectal cancer
should continue to be pursued.
About Burzynski Research Institute, Inc.
Burzynski Research Institute, Inc. (OTCBB:BZYR) is a
biopharmaceutical company committed to developing treatment for
cancer based on genomic and epigenomic principles. Research
and development efforts are focused on basic research and phase 3
clinical trials, particularly in the treatment of brain tumors and
other forms of cancer.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/burzynski-research-institute-inc-announces-publication-of-phase-2-clinical-study-in-metastatic-colon-adenocarcinoma-of-the-liver-300056848.html
SOURCE Burzynski Research Institute, Inc.